At the European Respiratory Society’s (ERS) Annual Congress held in Vienna September 1-5, 2012, we presented complete results from our Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients… Continue reading…
Posts Tagged with: Respiratory Syncytial Virus
May 29, 2012
Top-line Results of our Phase IIb Study of ALN-RSV01
We reported top-line results from our Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients. The primary endpoint of the study was the incidence of new or progressive bronchiolitis obliterans syndrome (BOS) at 180 days after RSV infection.
Read our press release Listen to our discussion of the top-line results View our presentation (449 KB PDF) View additional ALN-RSV program materialsJanuary 1, 2012
ALN-RSV Historical Press Releases
For your convenience we have collected a list of historical releases that cover the historical progress of our clinical program for respiratory syncitial virus*
2012
30/05/2012Alnylam Announces Top-Line Results of Phase IIb Clinical Trial2011
29/11/2011Alnylam Completes Enrollment in Phase IIb Study2010
29/09/2010 Alnylam Publishes Results from Phase IIa 27/04/2010 Alnylam Publishes Results from Phase II GEMINI Trial with ALN-RSV01 22/02/2010 Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV012009
20/07/2009 Alnylam and Cubist Announce Complete Data from Phase II Study 08/06/2009 Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II 08/06/2009 Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 09/01/2009 Alnylam and Cubist Form Strategic Collaboration2008
19/06/2008 Alnylam and Kyowa Hakko Form Alliance 09/04/2008 Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability 25/02/2008 Alnylam to Webcast Conference Call to Discuss Phase II GEMINI Data for ALN-RSV01 23/01/2008 Alnylam Reports Positive Phase II Data for ALN-RSV012007
13/12/2007 Alnylam Reports Continued Progress in Clinical Development of ALN-RSV01 26/06/2007 Alnylam Initiates Phase II Clinical Trial2006
28/11/2006 Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01 11/10/2006 Alnylam Initiates Phase I Clinical Study of Inhaled Formulation of ALN-RSV01 30/04/2006 Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01 25/04/2006 Alnylam to Present Phase I Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV
November 10, 2010
Viral load drives disease in humans experimentally infected with respiratory syncytial virus
April 26, 2010
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.
July 30, 2009
Alnylam RNAi Roundtable: ALN-RSV Program
In July 2009, we held an RNAi Roundtable focused on our ALN-RSV program.
ALN-RSV RNAi Roundtable, July 2009 (1.3MB PPT)December 26, 2007
